Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Oncorus, Inc. (ONCR : NSDQ)
 
 • Company Description   
Oncorus Inc. is a clinical stage biopharmaceutical company. It is focused on developing viral immunotherapies to transform outcomes for cancer patients. The company's product candidate includes ONCR-177, which is in clinical stage. Oncorus Inc. is based in CAMBRIDGE, Mass.

Number of Employees: 82

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.20 Daily Weekly Monthly
20 Day Moving Average: 128,066 shares
Shares Outstanding: 25.88 (millions)
Market Capitalization: $31.06 (millions)
Beta: 4.27
52 Week High: $17.79
52 Week Low: $1.03
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -14.29% -6.08%
12 Week -53.13% -49.14%
Year To Date -77.23% -72.92%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
50 Hampshire Street Suite 401
-
Cambridge,MA 02139
USA
ph: 857-320-6400
fax: -
ir@oncorus.com http://www.oncorus.com
 
 • General Corporate Information   
Officers
Theodore (Ted) Ashburn - Chief Executive Officer;President
Mitchell Finer - Chairman of the Board of Directors
John McCabe - Chief Financial Officer
Scott Canute - Director
Luke Evnin - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 68236R103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/03/22
Share - Related Items
Shares Outstanding: 25.88
Most Recent Split Date: (:1)
Beta: 4.27
Market Capitalization: $31.06 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.74 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.66 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.27
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -30.19%
vs. Previous Quarter: 10.39%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -50.39
12/31/21 - -42.00
09/30/21 - -36.51
ROA
03/31/22 - -35.09
12/31/21 - -30.66
09/30/21 - -27.48
Current Ratio
03/31/22 - 8.45
12/31/21 - 6.16
09/30/21 - 11.98
Quick Ratio
03/31/22 - 8.45
12/31/21 - 6.16
09/30/21 - 11.97
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 4.41
12/31/21 - 5.04
09/30/21 - 5.73
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©